Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.

You may also be interested in...

Genzyme’s Lumizyme REMS Eliminated Due To Expanded Indication

FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.

FDA Drops Restricted Access Requirement For Amgen’s Nplate And GSK’s Promacta

FDA’s decision to modify the risk program for thrombocytopenia treatments may influence CMS to drop Nplate from its list of potential National Coverage Determinations.

GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market

GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts